Litigation Details for Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)

Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)

Docket		Date Filed	2023-01-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,129,343; 8,536,122
Link to Docket	External link to docket

Details for Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-27	1	Complaint	United States Patent Nos. 8,129,343 (the “’343 Patent”), 8,536,122 (the “’122 Patent”), 9,764,003 (the… THE PATENTS-IN-SUIT U.S. Patent No. 8,129,343 73. The allegations…(the “’003 Patent”), 10,888,605 (the “’605 Patent”), and 11,318,191 (the “’191 Patent”) (collectively…number of patent litigation lawsuits involving the validity and/or infringement of patents held by branded… claim of the Asserted Patents, and/or that the claims of the Asserted Patents allegedly are invalid	External link to document
2023-06-22	28	Notice of Service	Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191… 27 January 2023 1:23-cv-00101 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-01-27	3	ANDA Form	Deadline: ________________________ * U.S. Patent No. 8,129,343 expires on 12/5/2031; ;%:% 8<L@GL 7H%… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 12/17/2022. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 6/17/… SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG…See Below* Date of Expiration of Patent: ________________________	External link to document